Abstract 1953: Peptidoglycan Recognition Protein-1 is Associated with Coronary and Peripheral Atherosclerosis: Observations from the Dallas Heart Study
Peptidoglycan Recognition Protein-1 (PGLYRP-1) is part of the innate immune system that recognizes bacterial cell wall peptidoglycan, which is present in atherosclerotic plaque. We performed a cross-sectional study to assess the association between PGLYRP-1 and multiple atherosclerosis phenotypes. PGLYRP-1 was measured in 3222 subjects in the Dallas Heart Study, a probability-based population sample. Coronary calcium (CAC) was measured by electron beam CT (n=2486), abdominal aortic wall thickness (AWT) by MRI (n=2312), and abdominal aortic plaque (AP) by MRI (n=2298). Increasing levels of PGLYRP-1 were associated with all traditional cardiac risk factors as well as C-reactive protein, cystatin C and monocyte chemoattractant protein-1. Higher PGLYRP-1 levels were associated with CAC (>10 Agatston units), particularly at a prespecified threshold > 95th percentile (figure⇓). In multivariable analyses adjusting for traditional risk factors, PGLYRP-1 >= 95th percentile vs. < 95th percentile was significantly associated with CAC (OR 2.1 95%CI 1.–3.3, p=0.001); AWT (p < 0.0001); and AP (p = 0.02). In this first reported clinical study of PGLYRP-1 in humans, PGLYRP-1 levels were independently associated with coronary calcium, aortic wall thickness, and aortic plaque, atherosclerosis phenotypes that represent different vascular beds and stages of atherosclerosis. These findings suggest links between infection, inflammation, and atherosclerosis, and support further exploration of PGLYRP-1 as a biomarker and mediator of atherosclerosis.